Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01057901 |
Recruitment Status :
Terminated
(Study terminated for administrative reasons.)
First Posted : January 28, 2010
Results First Posted : June 17, 2014
Last Update Posted : June 17, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Sexual Dysfunctions, Psychological | Drug: Flibanserin Drug: Placebo | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 748 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | 24 - Week Flibanserin 100mg for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in Noth America |
Study Start Date : | January 2010 |
Actual Primary Completion Date : | January 2011 |
Actual Study Completion Date : | January 2011 |
Arm | Intervention/treatment |
---|---|
Experimental: Flibanserin 100 mg
Flibanserin 100 mg administered at bedtime
|
Drug: Flibanserin
Flibanserin 100mg administered at bedtime for 24 weeks |
Placebo Comparator: Placebo
This is the matched placebo which will be administered two tablets daily at bedtime.
|
Drug: Placebo
This is the matched placebo which will be administered two tablets daily at bedtime. |
- Change From Baseline in the Number of Satisfying Sexual Events [ Time Frame: baseline to 24 weeks ]
The change from baseline in the number of SSE's as measured by the eDiary. The calculation of Satisfying Sexual Event (SSEs) will be standardized to a 28-day period according to the below formula:
Total monthly events = 28 x (sum of the number of events) / (sum of number of days entered).
"Satisfying" means gratifying, fulfilling, satisfactory, and/or successful for the patient. The partner's satisfaction is not the subject of this question.
- Change From Baseline in the Score on the Female Sexual Function Index (FSFI) Desire Domain [ Time Frame: baseline to 24 weeks ]The Female Sexual Function Index (FSFI) is a brief, multidimensional, self-administered questionnaire for assessing key domains of sexual function in women. The scale consists of 19 items that assess sexual function over the past four weeks and yields scores in six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. The two items in the desire domain are scored from 1 to 5 (1 is lowest level of desire and 5 is the highest level of desire). The raw scores of the two items are added together and then multiplied by the domain factor of 0.6. Thus, the score of the desire domain ranges from 1.2 (lowest level of desire) to 6.0 (highest level of desire). For the entire instrument, each of the six domains contributes a maximum of 6 points to the total. Scores on the full scale range from a minimum of 2 to a maximum of 36.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 35 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
- Naturally postmenopausal women of any age with at least one ovary
- Diagnosis of Hypoactive Sexual Desire Disorder, generalized acquired type,of at least six months duration
- Stable, monogamous heterosexual relationship for at least one year
- Willing to discuss sexual issues
- Willing to engage in sexual activity at least once a month
- Normal Pap smear
- Normal mammogram
- Normal uterine lining
- Able to comply with daily use of handheld data entry device
Exclusion criteria:
- Sexual dysfunctions other than HSDD, such as Sexual Aversion Disorder, Substance-induced Sexual Dysfunction, Dyspareunia, Vaginismus, Gender Identity Disorder, Paraphilia and Sexual Dysfunction due to a General Medical Condition
- Partner with inadequately treated organic or psychosexual dysfunction
- Sexual function impaired by psychiatric disorder
- Sexual function impaired by gynecological disorder
- Major Depression
- Suicidal behavior or ideation
- Major life stress that could impair sexual function
- Substance abuse
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01057901
Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim |
Responsible Party: | Sprout Pharmaceuticals, Inc |
ClinicalTrials.gov Identifier: | NCT01057901 |
Other Study ID Numbers: |
511.156 |
First Posted: | January 28, 2010 Key Record Dates |
Results First Posted: | June 17, 2014 |
Last Update Posted: | June 17, 2014 |
Last Verified: | June 2014 |
Sexual Dysfunctions, Psychological Mental Disorders |